Shanghai Henlius Biotech, Inc. Class H
HHKEX:269649.42
HKD
-4.28
(-7.97%)
ISIN
CNE100003N76
Return %
Stock
S&P 500
1Y
-30.69
14.20
3Y
394.69
81.12
5Y
98.47
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jun Zhu
- Full Time Employees
- 3,762
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building B8 Shanghai SH China 200233
- IPO Date
- Sep 25, 2019
- Website
- henlius.com
- Similar Companies
- Business
- Shanghai Henlius Biotech, Inc. stands as a global biopharmaceutical firm, deeply invested in the discovery, production, and commercialization of advanced biologic therapies. The company maintains a strategic focus on critical therapeutic areas, including various oncology indications, autoimmune disorders, and ophthalmology. Its portfolio of marketed products encompasses several significant biosimilars and innovative monoclonal antibodies. Noteworthy offerings include HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection (also known as HERCESSI™ in the U.S. and Zercepac® in Europe) approved for HER2-positive breast and metastatic gastric cancers across China, Europe, and the U.S.; HANDAYUAN, an adalimumab injection targeting conditions like rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; and HANBEITAI, a bevacizumab injection for metastatic colorectal cancer and non-squamous non-small cell lung cancer. Furthermore, HANSIZHUANG (serplulimab, or Hetronifly® in Europe), an anti-PD-1 monoclonal antibody, is a key innovative product, notably the world's first approved for the first-line treatment of extensive small cell lung cancer, and is also indicated for microsatellite instability-high solid tumors and squamous non-small cell lung cancer. The company also brought POHERDY® (pertuzumab-dpzb) to the U.S. market in partnership with Organon, marking the first pertuzumab biosimilar for HER2-positive breast cancers in the region. Additionally, denosumab biosimilars, BILDYOS® and BILPREVDA®, have secured European approval. Henlius actively cultivates a robust pipeline comprising over fifty diverse molecules, including novel monoclonal antibodies, multi-specific antibodies, antibody-drug conjugates, and fusion proteins. Key pipeline candidates include HLX04-O for wet age-related macular degeneration and HLX22, an innovative anti-HER2 monoclonal antibody that has received U.S. Orphan Drug Designation for gastric cancer. The company employs a "Combo+Global" strategy, with serplulimab serving as a foundational element for various combination therapies currently undergoing clinical evaluation. Operating with an integrated biopharmaceutical model, Henlius oversees the entire product lifecycle from research and development to manufacturing and global sales. Its manufacturing facilities in Shanghai are certified under GMP standards by regulatory bodies in China, Europe, and the U.S., supporting its international ambitions. The company has forged a broad commercial presence in mainland China through its dedicated sales force, while expanding its global footprint through strategic partnerships across Asia, Europe, North America, South America, and Oceania. Founded in 2010 and headquartered in Shanghai, China, Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. In 2023, the company achieved its first full year of profitability, reporting revenues exceeding RMB 5.39 billion.
Company News
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints